![Ian Gust](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ian Gust
Directeur/Membre du Conseil chez
BIOTA HOLDINGS LTD.
Profil
Ian David Gust is currently the Chairman at Bio21 Australia Ltd. and a Director at Opal Therapeutics, Inc. He is also an Independent Non-Executive Director at Biota Holdings Pty Ltd., a Director at the Australian International Health Institute, a Director at the Pediatric Dengue Vaccine Initiative, and a Professorial Fellow at the University of Melbourne.
In the past, Dr. Gust has worked as the Director of Research & Development at CSL Ltd. from 1990 to 2000.
He was also a Director at the International AIDS Vaccine Initiative, Inc. from 2010 to 2011.
Additionally, he served as a Non-Executive Director at Opal Therapeutics Pty Ltd., McFarlane Burnet Centre For Medical Research, and Aviragen Therapeutics, Inc. Furthermore, he was a Trustee at the International Vaccine Institute in 2006.
Postes actifs de Ian Gust
| Sociétés | Poste | Début |
|---|---|---|
| BIOTA HOLDINGS LTD. | Directeur/Membre du Conseil | 27/07/2001 |
Australian International Health Institute | Directeur/Membre du Conseil | 09/02/2011 |
Pediatric Dengue Vaccine Initiative | Directeur/Membre du Conseil | 09/02/2011 |
Bio21 Australia Ltd. | Président | 25/01/2012 |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Ian Gust
| Sociétés | Poste | Fin |
|---|---|---|
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines | Directeur/Membre du Conseil | 01/01/2006 |
| CSL LIMITED | Directeur Technique/Scientifique/R&D | 01/01/2000 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an anti-infective drug development company | Directeur/Membre du Conseil | - |
McFarlane Burnet Centre For Medical Research | Directeur/Membre du Conseil | - |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
61
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
CSL Ltd.
 CSL Ltd. BiotechnologyHealth Technology Develops and manufactures medicines that treat people with rare and serious diseases | Health Technology |
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops vaccines for AIDS | Health Technology |
Opal Therapeutics, Inc. | |
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Operates as an anti infective drug development company | Health Technology |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Opal Therapeutics Pty Ltd.
 Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops immunotherapy for HIV and Hepatitis C & chronic infection | Health Technology |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services Develops and distributes vaccines | Commercial Services |
Australian International Health Institute | |
Pediatric Dengue Vaccine Initiative | |
Bio21 Australia Ltd. | |
McFarlane Burnet Centre For Medical Research | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an anti-infective drug development company | Health Technology |
